Phathom Pharmaceuticals (PHAT) Revenue (2023 - 2026)

Phathom Pharmaceuticals (PHAT) has 4 years of Revenue data on file, last reported at $58.3 million in Q1 2026.

• Revenue for Q1 2026 came in at $58.3 million, up 104.43% year-over-year; the trailing twelve-month figure through Mar 2026 was $204.9 million (up 150.3% YoY), and the FY2025 annual result was $175.1 million, up 216.93% from the prior year.
• Revenue rose to $58.3 million in Q1 2026 per PHAT's latest filing, from $57.6 million in the prior quarter.
• Over five years, Revenue peaked at $58.3 million in Q1 2026 and troughed at $682000.0 in Q4 2023.
• A 4-year average of $28.9 million and a median of $29.1 million in 2024 frame the typical range for Revenue.
• The sharpest annual moves came in 2024 and 2025: Revenue jumped 4249.56% in 2024, then soared 94.12% in 2025.
• A 4-year view of Revenue shows it stood at $682000.0 in 2023, then jumped by 4249.56% to $29.7 million in 2024, then surged by 94.12% to $57.6 million in 2025, then grew by 1.25% to $58.3 million in 2026.
• Business Quant data shows PHAT's Revenue at $58.3 million in Q1 2026, $57.6 million in Q4 2025, and $49.5 million in Q3 2025.